Bayban’s AstraZeneca AZN Stock Holding History

Bayban’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.74K	Hold	20	–	–	﹤0.01%	490
2026 Q1	$3.87K	Hold	20	–	–	﹤0.01%	500
2025 Q4	$3.68K	Buy	+20	New	+$3.51K	﹤0.01%	484

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Prudential plc London, England, United Kingdom $18.4B AUM 23.98% 1-Year Est. Return

Bayban's AZN Position: Q2 2026 in Review

Bayban held its AstraZeneca (AZN) position steady in Q2 2026 at 20 shares worth $3.74K. The position accounts for ﹤0.01% of the portfolio, ranked #490.

Bayban first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.87K in Q1 2026. 1,425 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Bayban held 20 shares of AstraZeneca worth $3.74K as of Q2 2026.
Bayban left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up ﹤0.01% of Bayban's portfolio in Q2 2026, its #490 holding.
Bayban first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
Bayban's AstraZeneca position peaked at $3.87K in Q1 2026.
1,425 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Bayban's 13F filing for Q2 2026, filed 30 Jul 2026.